Trials / Completed
CompletedNCT01699152
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Tragara Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, dose escalation study.
Detailed description
The primary objective is to determine the highest dose of TG02 citrate that can be safely given to patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG02 citrate | TG02 citrate capsules |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2015-07-01
- Completion
- 2016-05-01
- First posted
- 2012-10-03
- Last updated
- 2019-07-25
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01699152. Inclusion in this directory is not an endorsement.